Levofloxacin: A Review of its Use in the Treatment of Bacterial Infections in the United States

Drugs

Volumn 63, Issue 24, 2003, Pages 2769-2802

  Croom, Katherine F ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute exacerbations of chronic bronchitis; Acute sinusitis; Antibacterials; Chronic bacterial prostatitis; Community acquired pneumonia; Genitourinary tract infections; Levofloxacin; Nosocomial pneumonia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; TIMENTIN;

ABDOMINAL PAIN; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CARDIOTOXICITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; IN VITRO STUDY; INSOMNIA; LIVER TOXICITY; MAXILLA SINUSITIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PROSTATITIS; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SHORT COURSE THERAPY; SINUSITIS; SKIN INFECTION; SKIN STRUCTURE; STREPTOCOCCUS PNEUMONIAE; TENDON DISEASE; TORSADE DES POINTES; UNITED STATES; URINARY TRACT INFECTION; VAGINITIS;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; RANDOMIZED CONTROLLED TRIALS; TISSUE DISTRIBUTION;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0347989421     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363240-00008     Document Type: Review

References (203)

1. Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002; 62(14): 2127-67
2. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002; 62 (1): 13-59
3. Hooper DC. Mode of action of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 6-10
4. Ortho-McNeil Pharmaceutical Inc. Levaquin (levofloxacin) tablets; Levaquin (levofloxacin) injection; Levaquin (levofloxacin in 5% dextrose) injection; prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc., 2003 Oct
5. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - sixth edition (M7-A6). MIC testing supplemental tables M100-S13 (M7). National Committee for Clinical Laboratory Standards, 2003; 23 (2)
6. White RL, Enzweiler KA, Friedrich LV, et al. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diagn Microbiol Infect Dis 2002 Jul; 43 (3): 207-17
7. Diekema DJ, Jones RN, Rolston KVI. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers. Diagn Microbiol Infect Dis 1999; 34: 37-43
8. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program. 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2): S81-93
9. Sahm DF, Weaver MK, Flamm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streprococcus pneumoniae in the United States: results from the TRUST 7 (2002-2003) surveillance study [abstract no. 201 plus poster]. 41st Annual Meeting IDSA; 2003 Oct 9-12; San Diego
10. Rolston KV, Frisbee-Hume S, LeBlanc BM, et al. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn Microbiol Infect Dis 2002 Oct; 44 (2): 187-94
11. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50
12. Deshpande LM, Jones RN. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). Diagn Microbiol Infect Dis 2000; 37: 139-42
13. Biedenbach DJ, Barrett MS, Croco MA, et al. BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998; 32: 45-50
14. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996; 25: 47-51
15. Kirby JT, Mutnick AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002 Aug; 43 (4): 303-9
16. Deshpande LM, Diekema DJ, Jones RN. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagn Microbiol Infect Dis 1999; 35: 81-8
17. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1867-74
18. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT Surveillance Study. Diagn Microbiol Infect Dis 2003 Apr; 45 (4): 251-9
19. Gordon KA, Beach ML, Biedenbach DJ. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002 Jun; 43 (2): 157-62
20. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agent Chemother 2003; 47 (6): 1875-81
21. Karlowsky JA, Kelly LJ, Thornsberrry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 2002; 19 (1): 21-31
22. Burgess DS, Nathisuwan S. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002 Sep; 44 (1): 35-41
23. Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998; 42: 953-5
24. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002 Dec; 50 (6): 1045-9
25. Howard W, Biedenbach DJ, Jones RN. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli. Clin Microbiol Infect 2002 Jun; 8 (6): 340-4
26. Zhanel GG, Palatnick L, Smith H, et al. ABT-492 demonstrates potent activity against Canadian lower respiratory tract infec-tion pathogens isolated in 2001-2002 [abstract plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 185
27. Hoban DJ, Biedenbach DJ, Mutnick AH, et al. Pathogen occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003 Apr; 45 (4): 279-85
28. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 2000; 31 Suppl. 2: S16-23
29. Thornsberry C, Karlowsky JA, Weaver MK, et al. Current view of antimicrobial susceptibility among common gram-negative pathogens: 2003 TRUST surveillance data [abstract 222 plus poster]. 41st Annual Meeting of IDSA; 2003 Oct 9-12; San Diego
30. Thornsberry C, Sahm DF, Weaver MK, et al. Antimicrobial susceptibilities of common pathogens causing nosocomial pneumonia: 2001-2003 TRUST surveillance. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
31. Appelbaum PC. Quinolone activity against anaerobes. Drugs 1999; 58 Suppl.: 60-4
32. Wexler HM, Molitoris E, Molitoris D, et al. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother 1998; 42: 984-6
33. Goldstein EJ, Citron DM, Hudspeth M, et al. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J Antimicrob Chemother 1998; 41: 391-6
34. Credito KL, Jacobs MR, Appelbaum PC. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1399-402
35. Hoellman DB, Kelly LM, Jacobs MR. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001; 45 (2): 589-92
36. Zhanel GG, Laing NM, Decorby M, et al. Pharmacodynamic (PD) activity of fluoroquinolones (FQ) in a mixed infection simulating an artificial bowel: effect of eradicating Bacteroides fragilis [poster no. A145]. 103rd American Society for Microbiology General Meeting; 2002 May 19-23; Salt Lake City
37. Horn R, Lavallée J, Robson HG. Susceptibility of the Bacteroides fragilis group to garenoxacin (BMS284756), other quinolones and standard antianaerobic agents [abstract no. E-60 plus poster 60]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
38. Wilcox MH, Fawley W, Freeman J, et al. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Agents Chemother 2000; 46: 551-5
39. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343 (26): 1925-32
40. Miller M, Cohen E, Consolacion N, et al. Control of hyperendemic nosocomial C. difficile-associated diarrhea by substitution of cephalosporins with ticar/clav & fluoroquinolones in the hospital formulary [abstract no. K-1369 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
41. Rao GG, Mahankali Rao CS, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697-701
42. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against {IChlamydia} {Ipneumoniae}. Antimicrob Agents Chemother 1992; 36 (7): 1573-4
43. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002 Apr; 8 (4): 214-21
44. Waites KB, Crabb DM, Bing X, et al. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003 Jan; 47 (1): 161-5
45. Roblin PM, Hammerschlag MR. In Vitro Activity of a New Antibiotic. NVP-PDF386 (VRC4887). against Chlamydia pneumoniae. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1447-8
46. Piddock LJV. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999; 58 Suppl. 2: 11-8
47. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34 Suppl. 1: S4-16
48. Karlowsky JA, Jones ME. Thornsberry C, et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003 May; 47 (5): 1672-80
49. Felmingham D, Reinert RR. Hirakata Y, et al. Increasing prevalence of anti microbial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002 Sep; 50 Suppl. S1: 25-37
50. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003 Apr 15; 36 (8): 963-70
51. Ho PL, Yung RWH, Tsang DNC, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659-65
52. Chen DK, McGeer A, de Azavedro JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-9
53. Ferraro M, Brown S, Harding I. Prevalence of fluoroquinolone resistance amongst Streptococcus pneumoniae isolated in the United States during the winter of 2000-01 [abstract no. C2-650]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 97
54. Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002 Sep; 44 (1): 77-84
55. Sahm DF, Peterson DE, Critchley IA, et al. Analaysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000; 44 (9): 2521-4
56. Smith HJ, Nichol KA, Palatnick L, et al. In vitro activity of ABT-492 against ciprofloxacin-resistant Streptococcus pneumoniae compared to eight other drugs [abstract plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 184
57. Bozdogan B, Kelly L, Jacobs MR, et al. Activity of DK-507k, a new fluoroquinolone, against quinolone non-susceptible Streptococcus pneumoniae compared to ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and sitafloxacin [abstract plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego. 189
58. Davidson RJ, MacKenzie H, Forward K, et al. Comparative activity of new generation fluoroquinolones against S. pneumoniae with documented topoisomerase IV (parC) and DNA gyrase (gyrA) mutations [abstract no. 825]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
59. Bast DJ, De Azavedo JCS, Duncan C, et al. Activity of newer fluoroquinolones against isolates of Streptococcus pneumoniae with increasing resistance to ciprofloxacin [abstract no. 1490]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco. 264
60. Zhanel GG, Roberts D, Waltky A, et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002; 49: 807-12
61. Jorgensen JH, Weigel LM, Ferraro MJ, et al. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA. parC, and parE loci. Antimicrob Agents Chemother 1999; 43: 329-34
62. Klepser ME, Ernst EJ, Petzold CR, et al. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45 (3): 673-8
63. Drugeon HB, Juvin ME, Bryskier A. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother 1999; 43 Suppl. C: 55-9
64. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 410-2
65. Davies TA, Pankuch GA, Dewasse BE, et al. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 1177-82
66. Kelly, LA, Thornsberry C, Jones ME, et al. Multidrug-resistant pneumococci isolated in the US: 1997-2001 TRUST Surveillance [abstract no. C2-2109]. Proceeedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, 142
67. Sahm DF, Thornsberry C, Jones ME, et al. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa from inpatient infections in the U.S.: 1999-2002 TRUST surveillance [abstract plus poster]. Annual Meeting Society for Critical Care Medicine (SCCM); 2003 Jan 30; San Antonio (TX)
68. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States. 1998 to 2001. Antimicrob Agents Chemother 2003 May; 47 (5): 1681-8
69. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279 (2): 125-9
70. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073-81
71. Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 Suppl. 1: 6-14
72. Ibrahim KH, Hovde LB, Ross G, et al. Microbiologic effectiveness of time-or concentration-based dosing strategies in Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002 Nov; 44 (3): 265-71
73. Lister PD. Pharmacodynamics of 750mg and 500mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002 Sep; 44 (1): 43-9
74. Drusano GL, Preston SL, Corrado M, et al. Target attainment analysis for levofloxacin (L) 750mg IV daily for nosocomial pneumonia using Monte Carlo simulation for common Gram-negative pathogens [abstract no. A-638]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
75. Preston SL, Drusano GL, Corrado M, et al. Pharmacodynamic analysis of levofloxacin (L) 750mg IV daily for nosocomial pneumonia [abstract plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
76. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25 (2): 485-506
77. Preston SL, Redell M, Chien SC, et al. Evaluation of the target attainment rate of levofloxacin and ciprofloxacin for intensive care unit patients. Proceedings of the 10th International Congress on Infectious Diseases; 2002 Mar 11-14; Singapore
78. Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology. Antimicrob Agents Chemother 1998; 42 (5); 1263-5
79. Fuchs PC, Barry AL, Brown SD. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin. J Chemother 1997; 9 (6): 391-3
80. Pendland SL, Diaz-Linares M, Garey KW, et al. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother 1999; 43: 2547-9
81. Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect of levofloxacin against pneumococci. Drugs 1999; 58 Suppl. 2: 378-80
82. Credito KL, Clark CL, Jacobs MR, et al. Post-antibiotic effect (PAE) of gemifloxacin (SB 265805) compared with five other quinolones against pneumococci [abstract no. 537]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 21
83. Spangler SK, Bajaksouzian S, Jacobs MR, et al. Postantibiotic effects of grepafloxacin compared to those of five agents against 12 Gram-positive and -negative bacteria. Antimicrob Agents Chemother 2000; 44: 186
84. Smith RP, Baltch AL, Ritz W, et al. Postantibiotic effect (PAE) measurement for levofloxacin and four other antibiotics against Legionella pneumophila, using mathematical modeling of the growth curve [abstract no. A109]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 34
85. Chien S-C, Rogge MC, Gilscon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41 (10): 2256-60
86. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3
87. Chien S-C, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 885-8
88. Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45 (7): 2122-5
89. Amsden GW, Graci DM, Cabelus LJ, et al. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. Chest 1999; 116: 115-9
90. Noel GJ, Abels R, Minton N, et al. Effects of three fluoroquinolones (FQs) on QTc intervals in healthy volunteers [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, 639a
91. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32 (2): 101-19
92. Lee L-J, Hafkin B, Lee I-D, et al. Effect of food and sucralfate on levofloxacin after a single oral dose of 500mg in male and female subjects. American Society for Microbiology [abstract no. A40]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 8
93. Langtry HD, Lamb HM. Levofloxacin: its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56 (3): 487-515
94. Taira K, Koga H, Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1993; 37: 1877-81
95. Gaja M, Higa F, Yamashiro T, et al. Penetration of levofloxacin, a new quinolone antibacterial agent, into human neutrophils. Chemotherapy 1992; 40: 64-7
96. Smith RP, Baltch AL, Franke MA, et al. Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 483-8
97. Chow AT, Chen A, Lattime H, et al. Penetration of levofloxacin into skin tissue after oral administration of 750mg once-daily doses. J Clin Pharm Ther 2002; 27: 143-50
98. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-22
99. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003 Aug; 47 (8): 2450-7
100. Drusano GL, Preston SL, Gotfried MH, et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46 (2): 586-9
101. Drusano GL, Preston SL, Gotfried MH, et al. The penetration of 750mg of levofloxacin administered intravenously into the epithelial lining fluid (ELF). Proceedings of the 10th International Congress on Infectious Diseases; 2002 Mar 11-14; Singapore
102. Kahn JB, Wiesinger BA, North D, et al. The penetration of levofloxacin (LVFX) into the prostate [abstract no. 250]. Clin Infect Dis 1998; 27: 967
103. Yamashita M, Sawada K, Chokyu H, et al. Prostatic tissue levels of levofloxacin [in Japanese]. Chemotherapy 1992; 40 Suppl. 3: 203-9
104. Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-51
105. Rodvold KA, Danziger LH, Gotfried MH, et al. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adult subjects. Antimicrob Agents Chemother 2003 Aug; 47 (8): 2450-7
106. Nagai H, Yamasaki T, Masuda M, et al. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993; 45 Suppl. 3: 259
107. Nakamori Y, Tsuboi E, Narui K, et al. Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections [in Japanese]. Jpn J Antibiot 1992; 45: 539-47
108. Okazaki O, Kojima C, Hakusui H, et al. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991; 35 (10): 2106-9
109. Gisclon LG, Curtin CR, Chien SC, et al. The pharmacokinetics (PK) of levofloxacin (LVFX) in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis [abstract no. A13]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans
110. Sowinski KM, Lucksiri A, Kays MB, et al. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. Am J Kidney Dis 2003 Aug; 42 (2): 342-9
111. Kees F, Hansen E, Bucher M, et al. Pharmacokinetics of levofloxacin in patients during continuous venovenous hemofiltration. Antiinfect Drugs Chemother 2000; 17 (1): 77
112. Traunmüller F, Thalhammer-Scherrer R, Locker G, et al. Single-dose pharmacokinetics of levofloxacin during continuous venovenous hemofiltration (CVVH) [abstract no. MoP247]. Clin Microbiol Infect 2000; 6 Suppl. 1: 203
113. Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in clinically ill patients. Antimicrob Agents Chemother 2001; 45 (10): 2949-54
114. Rogge MC, Chien S-C, Holland ML. Single-dose pharmacokinetics of levofloxacin: influence of age and gender [abstract]. 5th International Symposium on New Quinolones; 1994 Aug; Singapore
115. Goodwin SD, Gallis HA, Chow AT. et al. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994; 38 (4): 799-804
116. Chien SC, Chow AT, Rogge MC, et al. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997; 41 (8): 1765-9
117. Piscitelli SC, Spooner K, Baird B, et al. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999; 43 (9): 2323-7
118. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998; 42 (5): 1098-104
119. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002 Oct; 22 ( 10): 1216-25
120. Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992; 36 (10): 2270-4
121. Okimoto N, Niki YSR. Effect of levofloxacin on serum concentration of theophylline. Chemotherapy 1992; 40 Suppl. 3: 68-74
122. Gisclon LG, Curtin CR, Fowler CL, et al. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin [abstract no. A39]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco
123. Nakamura H, Ohtsuka T, Enomoto H, et al. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Ann Pharmacother 2001; 35: 691-3
124. Liao S, Palmer M, Fowler CA, et al. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers [abstract no. A42]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 8
125. Gheno G, Cinetto L. Levofloxacin-warfarin interaction [letter]. Eur J Clin Pharmacol 2001; 57: 427
126. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother 2002 Oct; 36 (10): 1554-7
127. Yamreudeewong W, Lower DL, Kilpatrick DM, et al. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. Pharmacotherapy 2003 Mar; 23 (3): 333-8
128. Gaitonde MD, Mendes P, House ESA, et al. The effects of cimetidine and probenecid on the pharmacokinetics of levofloxacin (LVFX) [abstract no. A41]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, 8
129. Capone D, Carrano R, Gentile A, et al. Pharmacokinetic interaction between tacrolimus and levofloxacin in kidney transplant recipients [abstract]. Nephrol Dial Transplant 2001; 16 (6): A207
130. Chien S-C, Rogge MC, Williams RR, et al. Absence of a pharmacokinetic interaction between digoxin and levofloxacin. J Clin Pharm Ther 2002; 27: 7-12
131. Villani P, Viale P, Signorini L, et al. Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy. Antimicrob Agents Chemother 2001; 45 (7): 2160-2
132. Hautamaki D, Kureishi A, Warner J, et al. Five day moxifloxacin compared to 7 day levofloxacin therapy in the treatment of acute exacerbations of chronic bronchitis (AECB) [abstract]. Am J Respir Crit Care Med 2001; 163 (5): A771
133. Kahn JB, Wiesenger BA, Olson WH, et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality [poster]. Proceedings of the 7th International Symposium of New Quinolones; 2001 Jun 10-12; Edinburgh, 115
134. Tennenberg AM, Khashab MM, Wiesenger BA, et al. Prospective evaluation of levofloxacin in a study of community acquired Legionnaires' disease. American Thoracic Society (ATS) Meeting 2003; May 16-18; Seattle (WA)
135. Lode H, Mauch H, Schafer V, et al. Influence of levofloxacin compared with clarithromycin on the infection-free interval in patients with chronic bronchitis [abstract no. P1122]. 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10-13; Glasgow
136. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 761-3
137. Ortho-McNeil Pharmaceutical Inc. Levaquin receives FDA approval for five-day treatment of community-acquired pneumonia [online]. Available from URL: http://www.ortho-mcneil.com/news [Accessed 2003 Oct 29]
138. Ortho-McNeil Pharmaceutical Inc. Nosocomial pneumonia indication approved for LEVAQUIN(R) [media release]. 2002
139. Kahn JB, Oross MP, Wu S-C, et al. Levofloxacin in the treatment of pneumonia due to Pseudomonas aeruginosa. Chest 2002 Oct; 122Suppl.: 164 plus poster presented at Chest 2002 Nov 2-7; San Diego
140. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin
141. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets with levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736-51
142. File Jr TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41 (9): 1965-72
143. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002 Aug; 24 (8): 1292-308
144. Sullivan JG, McElroy AD, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy: treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999; 20 (11): S49-59
145. Wiesinger BA, Kahn JB, Williams RR, et al. Efficacy of levofloxacin in the treatment of community-acquired pneumonia due to penicillin-and macrolide-resistant Streptococcus pneumoniae [abstract no. P404]. J Antimicrob Chemother 1999; 44 Suppl. A: 130
146. Kahn JB, Wiesenger BA, Drucker LM, et al. Cumulative clinical trial experience with levofloxacin in pneumococcal bacteremia [abstract no. 8.21 plus poster]. 6th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICAMS-KO-6); 2002 Jan 23-26; Bologna
147. Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Therapeutics 2001; 23 (3): 425-39
148. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346 (10): 747-50
149. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001; 184: 794-8
150. Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003 Aug 1; 37 (3): 376-81
151. Rittenhouse BE, Stinnett AA, Dulisse B, et al. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia. Pharmacol Ther 1999; 24 (4): 169-79
152. Rittenhouse BE, Stinnett AA, Dulisse B, et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care 2000; 6 (3): 381-9
153. Rai S, Farag B, Mifune Y, et al. Levofloxacin vs. ceftriaxone/ azithromycin in the treatment of community-acquired pneumonia: a length of stay comparison [abstract no. P1123]. 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10-13; Glasgow
154. Richerson MA, Ambrose PG, Quintiliani R, et al. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998; 7 (5): 227-33
155. Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000; 22 (2): 250-64
156. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998; 7 (2): 101-9
157. Amsden GW, Baird IM, Simon S, et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003 Mar; 123 (3): 772-7
158. Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother 1999; 43 Suppl. C: 83-90
159. Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43: 529-39
160. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5-and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001; 18: 503-12
161. Adelglass J, DeAbate CA, McElvaine P, et al. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999; 120: 320-7
162. Adelglass J, Jones TM, Ruoff G, et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998; 18 (6): 1255-63
163. Lasko B, Lau CY, Saint-Pierre C, et al. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. Canadian Sinusitis Study Group. J Int Med Res 1998; 26: 281-91
164. Bundrick W, Heron SP, Ray P. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62 (3): 537-41
165. Nickel JC, Downey J, Clark J, et al. Levofloxacin treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men: a randomized placebo controlled multicenter trial [abstract no. 104]. J Urology 2003; 169 Suppl.: 27
166. Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med 1999; 106: 327-34
167. Richard GA, DeAbate CA, Ruoff GE, et al. A double-blind, randomized trial of the efficacy and safety of short-course, once-daily levofloxacin versus ofloxacin twice daily in uncomplicated urinary tract infections. Infect Dis Clin Pract 2000; 9: 323-9
168. Klimberg IW, Cox II CE, Fowler CL, et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998; 51 (4): 610-5
169. Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52: 51-5
170. Nichols RL, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997; 90 (12): 1193-200
171. Nicodemo AC, Robledo JA, Jasovich A, et al. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998; 52 (2): 69-74
172. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001; 45 (8): 2358-62
173. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002 Aug 15; 35 (4): 381-9
174. Wiesenger BA, Noel GJ, Tennenberg AM, et al. The safety of high-dose (750-mg qd) levofloxacin [poster]. Proceedings of the 10th International Congress on Infectious Diseases; 2002 Mar 11-14; Singapore
175. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352-64
176. Boccumini LE, Fowler CL, Campbell TA, et al. Photoreaction potential of orally administered levofloxacin in healthy subjects. Ann Pharmacother 2000; 34: 453-8
177. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58 Suppl. 2: 37-42
178. Lewis JR, Gums JG, Dickensheets DL. Levofloxacin-induced bilateral Achilles tendonitis. Ann Pharmacother 1999; 33: 792-5
179. Connelly S, Bayliff C, Mehta S. Levofloxacin-induced bilateral Achilles tendinopathy. Can J Hosp Pharm 2002 Jun; 55: 212-4
180. Haddow LJ, Chandra Sekhar M, Hajela V, et al. Spontaneous Achilles tendon rupture in patients treated with levofloxacin. J Antimicrob Chemother 2003 Mar; 51 (3): 747-8
181. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl. 3: 32-7
182. Harding I, Simpson I. Levofloxacin: low potential for hepatobiliary adverse reactions [abstract no. P851]. Clin Microbiol Infect 2001; 7 Suppl. S1: 164
183. Schwalm J-D, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ 2003 Apr 1; 168 (7): 847-8
184. Menzies DJ, Dorsainvil PA, Cunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113: 232
185. O'Hare M, Simpson IN. Levofloxacin: low potential for cardiovascular adverse reactions. Clin Microbiol Infect 2001; 7 Suppl. 1: 164-5
186. Sadek M, Bharadwaj R, Cohen H, et al. The effects of intravenous levofloxacin on the electrocardiographic QT interval. Pharmacotherapy 2002 Oct; 22: 1327-8
187. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin [letter]. Am J Med 1999; 107: 528-9
188. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21 (12): 1468-72
189. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003 Apr; 73 (4): 292-303
190. Paltoo B, O'Donoghue S, Moussavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. PACE 2001; 24: 895-7
191. Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002 Sep; 24 (9): 1414-25
192. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000: 31 (2): 347-82
193. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia; diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Resp Crit Care Med 2001; 163: 1730-54
194. Campbell Jr GD. The role of antimicrobial therapy in acute exacerbations of chronic bronchitis. Am J Med Sci 1999; 318 (2): 84-8
195. Craven DE, De Rosa FG. Thornton D. Nosocomial pneumonia: emerging concepts in diagnosis, management, and prophylaxis. Curr Opin Crit Care 2002; 8: 421-9
196. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Resp Crit Care Med 1996; 153: 1711-25
197. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903
198. Beringer PM, Wong-Beringer A, Rho JR. Economic aspects of antibacterial adverse effects. Pharmacoeconomics 1998; 13 (1 Pt 1): 35-49
199. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med 2002 Jul 8; 113 Suppl. 1A: 45S-54S
200. Bjerklund Johansen TE, Grüneberg RN, Guibert J, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998; 34: 457-66
201. Bertino Jr J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817
202. Bayer Pharmaceuticals Corporation. Avelox (moxifloxacin hydrochloride) tablets; Avelox I.V. (moxifloxacin hydrochloride in sodium chloride injection): prescribing information. West Hacen (CT): Bayer Pharmaceuticals Corporation, 2003 Mar
203. Bristol-Myers Squibb Company. Tequin (gatifloxacin) tablets; injection: prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2002 Dec